Fineline Cube

Follow:
14778 Articles
AstraZeneca's Fasenra Approved by EU for Eosinophilic Granulomatosis Treatment
CompanyDrug

AstraZeneca’s Fasenra Approved by EU for Eosinophilic Granulomatosis Treatment

AbbVie Inks $1.4 Billion Deal to Acquire Alzheimer's Drug Developer Aliada Therapeutics
CompanyDrug

AbbVie Inks $1.4 Billion Deal to Acquire Alzheimer’s Drug Developer Aliada Therapeutics

CSPC Pharmaceutical's SYS6020 Receives NMPA Approval for Myasthenia Gravis Clinical Trial
CompanyDrug

CSPC Pharmaceutical’s SYS6020 Receives NMPA Approval for Myasthenia Gravis Clinical Trial

Eli Lilly’s Ebglyss Shows Positive Results in Phase III Study for Atopic Dermatitis Patients Previously Treated with Dupilumab
CompanyDrug

Eli Lilly’s Ebglyss Shows Positive Results in Phase III Study for Atopic Dermatitis Patients Previously Treated with Dupilumab

CANbridge Pharmaceuticals Scales Back US Operations, Focuses on China for R&D and Commercialization
Company

CANbridge Pharmaceuticals Scales Back US Operations, Focuses on China for R&D and Commercialization

Biogen's Felzartamab Demonstrates Promising Results in Phase II Study for IgA Nephropathy
CompanyDrug

Biogen’s Felzartamab Demonstrates Promising Results in Phase II Study for IgA Nephropathy

Humanwell Healthcare Receives NMPA Approval for Chemically Synthesized Semaglutide Clinical Trial
CompanyDrug

Humanwell Healthcare Receives NMPA Approval for Chemically Synthesized Semaglutide Clinical Trial

RiboX Therapeutics' Circular RNA Therapy RXRG001 Gets FDA Green Light for Dry Mouth Clinical Trial
CompanyDrug

RiboX Therapeutics’ Circular RNA Therapy RXRG001 Gets FDA Green Light for Dry Mouth Clinical Trial

AstraZeneca's Zoladex Receives NMPA Approval for Higher Dosage Form in Breast Cancer Treatment
CompanyDrug

AstraZeneca’s Zoladex Receives NMPA Approval for Higher Dosage Form in Breast Cancer Treatment

"MicuRx Pharmaceuticals' Antibiotic MRX-5 Completes Successful Phase I Clinical Trial in Australia
CompanyDrug

MicuRx Pharmaceuticals’ Antibiotic MRX-5 Completes Successful Phase I Clinical Trial in Australia

NMPA's CDE Prioritizes Marketing Filings for Innovative Drugs with Priority Review Status
Policy / Regulatory

NMPA’s CDE Prioritizes Marketing Filings for Innovative Drugs with Priority Review Status

Wantai Biological's P85 Ab Detection Kit Receives NMPA Approval for Nasopharyngeal Carcinoma Screening
CompanyMedical Device

Wantai Biological’s P85 Ab Detection Kit Receives NMPA Approval for Nasopharyngeal Carcinoma Screening